This clinical trial is focused on studying a type of cancer called Diffuse Large B-Cell Lymphoma (DLBCL), which is a condition where the body produces abnormal B-cells, a type of white blood cell. The study is specifically for patients whose DLBCL has returned or has not responded to previous treatments. The trial will explore the effects of a new treatment combination that includes the medications Glofitamab, Gemcitabine, and Oxaliplatin. Glofitamab is a type of protein-based medication, while Gemcitabine and Oxaliplatin are chemotherapy drugs that help stop the growth of cancer cells.

The purpose of the study is to understand how this combination of medications affects a condition known as Cytokine Release Syndrome (CRS), which can occur when the immune system reacts strongly to certain treatments. The study will monitor how often CRS happens and how severe it is when patients receive the treatment. Patients will receive the medications through an intravenous (IV) infusion, which means the drugs are given directly into the bloodstream through a vein. The study will also look at how well patients tolerate the treatment and any side effects they might experience.

Participants in the study will receive the treatment over a period of time, with regular check-ups to monitor their health and the effects of the treatment. The study aims to provide valuable information on the safety and effectiveness of this treatment combination for patients with relapsed or refractory DLBCL. The trial is expected to continue for several years, allowing researchers to gather comprehensive data on the treatment’s impact on patients’ health and quality of life.